This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Anderson, P. M. Articles by Bruland, O. S. Search for Related Content PubMed PubMed Citation Articles by Anderson, P. M. Articles by Bruland, O. S. Social Bookmarking                            What's this?

High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients With Osteosarcoma and Bone Metastases

From the Mayo Clinic, Rochester, MN; and Norwegian Radium Hospital, Oslo, Norway.

Address reprint requests to Peter M. Anderson, MD, PhD, Mayo Clinic, Department of Pediatrics, 200 First St SW, Rochester, MN 55905; email: anderson.peter{at}mayo.edu

PURPOSE: Samarium-153 ethylene diamine tetramethylene phosphonate (¹⁵³Sm-EDTMP), a bone-seeking radiopharmaceutical, provides therapeutic irradiation to osteoblastic bone metastases. Because the dose-limiting toxicity of ¹⁵³Sm-EDTMP is thrombocytopenia, a dose-escalation trial using peripheral-blood progenitor cells (PBPCs) or marrow support was conducted to treat metastatic bone cancer.

PATIENTS AND METHODS: Patients with locally recurrent or metastatic osteosarcoma or skeletal metastases avid on bone scan were treated with 1, 3, 4.5, 6, 12, 19, or 30 mCi/kg of ¹⁵³Sm-EDTMP.

RESULTS: Thirty patients were treated with ¹⁵³Sm-EDTMP. Transient symptoms of hypocalcemia were seen at 30 mCi/kg. Estimates of radioisotope bound to bone surfaces and marrow radiation dose were linear with injected amount of ¹⁵³Sm-EDTMP. Cytopenias also occurred in all subjects and were dose-related. At day +13 after ¹⁵³Sm-EDTMP, residual whole-body radioactivity was 1% to 65% of whole-body radioactivity considered safe for PBPC infusion, 3.6 mCi. After PBPC or marrow infusion on day +14 after ¹⁵³Sm-EDTMP, recovery of hematopoiesis was problematic in two patients at the 30 mCi/kg dose infused with less than 2 x 10⁶ CD34⁺/kg on day +14, but not in other patients. Reduction or elimination of opiates for pain was seen in all patients. Patients had no adverse changes in appetite or performance status.

CONCLUSION: ¹⁵³Sm-EDTMP with PBPC support can provide bone-specific therapeutic irradiation (estimates of 39 to 241 Gy). Hematologic toxicity at 30 mCi ¹⁵³Sm-EDTMP/kg requires PBPC grafts with more than 2 x 10⁶ CD34⁺/kg to overcome myeloablative effects of skeletal irradiation. Nonhematologic side effects are minimal.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				V. O. Lewis, M. G. Ozawa, M. T. Deavers, G. Wang, T. Shintani, W. Arap, and R. Pasqualini The Interleukin-11 Receptor {alpha} as a Candidate Ligand-Directed Target in Osteosarcoma: Consistent Data from Cell Lines, Orthotopic Models, and Human Tumor Samples Cancer Res., March 1, 2009; 69(5): 1995 - 1999. [Abstract] [Full Text] [PDF]

				M. Chakraborty, E. K. Wansley, J. A. Carrasquillo, S. Yu, C. H. Paik, K. Camphausen, M. D. Becker, W. F. Goeckeler, J. Schlom, and J. W. Hodge The Use of Chelated Radionuclide (Samarium-153-Ethylenediaminetetramethylenephosphonate) to Modulate Phenotype of Tumor Cells and Enhance T Cell-Mediated Killing Clin. Cancer Res., July 1, 2008; 14(13): 4241 - 4249. [Abstract] [Full Text] [PDF]

				P. M. Anderson, G. A. Wiseman, L. Erlandson, V. Rodriguez, B. Trotz, S. A. Dubansky, and K. Albritton Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma Clin. Cancer Res., October 1, 2005; 11(19): 6895 - 6900. [Abstract] [Full Text] [PDF]

				G. M. Reisfield, E. B. Silberstein, and G. R. Wilson Radiopharmaceuticals for the palliation of painful bone metastases American Journal of Hospice and Palliative Medicine, January 1, 2005; 22(1): 41 - 46. [Abstract] [PDF]

				D. Lussier, A. G. Huskey, and R. K. Portenoy Adjuvant Analgesics in Cancer Pain Management Oncologist, September 1, 2004; 9(5): 571 - 591. [Abstract] [Full Text] [PDF]

				N. Marina, M. Gebhardt, L. Teot, and R. Gorlick Biology and Therapeutic Advances for Pediatric Osteosarcoma Oncologist, July 1, 2004; 9(4): 422 - 441. [Abstract] [Full Text] [PDF]

				C. d. L. Davies, L. M. Lundstrom, J. Frengen, L. Eikenes, O. S. Bruland, O. Kaalhus, M. H. B. Hjelstuen, and C. Brekken Radiation Improves the Distribution and Uptake of Liposomal Doxorubicin (Caelyx) in Human Osteosarcoma Xenografts Cancer Res., January 15, 2004; 64(2): 547 - 553. [Abstract] [Full Text] [PDF]

				H. J. Siegel, J. V. Luck Jr, and M. E. Siegel Advances in Radionuclide Therapeutics in Orthopaedics J. Am. Acad. Ortho. Surg., January 1, 2004; 12(1): 55 - 64. [Abstract] [Full Text] [PDF]

				R. Gorlick, P. Anderson, I. Andrulis, C. Arndt, G. P. Beardsley, M. Bernstein, J. Bridge, N.-K. Cheung, J. S. Dome, D. Ebb, et al. Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary Clin. Cancer Res., November 15, 2003; 9(15): 5442 - 5453. [Abstract] [Full Text] [PDF]

				S. Giralt, W. Bensinger, M. Goodman, D. Podoloff, J. Eary, R. Wendt, R. Alexanian, D. Weber, D. Maloney, L. Holmberg, et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials Blood, October 1, 2003; 102(7): 2684 - 2691. [Abstract] [Full Text] [PDF]

				K. L. Weber and M. C. Gebhardt What's New in Musculoskeletal Oncology J. Bone Joint Surg. Am., March 31, 2003; 85(4): 761 - 767. [Full Text] [PDF]

				P. M. Anderson Effectiveness of Radiotherapy for Osteosarcoma That Responds to Chemotherapy Mayo Clin. Proc., February 1, 2003; 78(2): 145 - 146. [PDF]

				T. Ozaki, S. Flege, M. Kevric, N. Lindner, R. Maas, G. Delling, R. Schwarz, A. R. von Hochstetter, M. Salzer-Kuntschik, W. E. Berdel, et al. Osteosarcoma of the Pelvis: Experience of the Cooperative Osteosarcoma Study Group J. Clin. Oncol., January 15, 2003; 21(2): 334 - 341. [Abstract] [Full Text] [PDF]

				C. Franzius, A. Schuck, and S. S. Bielack High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients With Osteosarcoma and Bone Metastases J. Clin. Oncol., April 1, 2002; 20(7): 1953 - 1954. [Full Text] [PDF]